![]() ![]() In Q1, we have maintained the work from home policies we adopted in 2020 and are continuing to monitor the pandemic closely as we assess the right timing for a more general return to the workplace. Our internal COVID transmission rates remain extremely low, and we are starting to benefit from the vaccination programs. Overall, we continue to be very pleased with our employee safety despite the increases in COVID in some areas of the world. We continue our focus on the 3 areas previously communicated, the ongoing safety of our employees continuing manufacturing operations to ensure product supply and support of our customers and making sure we continue to make progress on our core strategies. As expected, COVID continues to have an impact on our operations, but as previously communicated, we have now adapted well to this environment, and our employees around the world continue to perform to the highest standards. Thank you, Ilan, and I'd like to take just a few minutes to review our current state of operations around the world. Before I begin the detailed first quarter discussion, I would like to ask Andy Last, our Chief Operating Officer, to provide an update on Bio-Rad's operations in light of the current pandemic-related environment that we are experiencing globally. Thank you all for joining us, and we hope that you and your families are well and staying healthy during these challenging times. ![]() I will now turn the call over to Ilan Daskal, our Executive Vice President and Chief Financial Officer. Investors should review the reconciliation of these non-GAAP measures to the comparable GAAP results contained in our earnings release. Our remarks today will also include references to non-GAAP net income and non-GAAP diluted income per share, which are financial measures that are not defined under generally accepted accounting principles. The company does not intend to update any forward-looking statements made during the call today. You should not place undue reliance on these forward-looking statements, and I encourage you to review our filings with the SEC where we discuss in detail the risk factors in our business. We cannot be certain that Bio-Rad's responses to the pandemic will be successful, that the demand for Bio-Rad's COVID-19-related products is sustainable or that Bio-Rad will be able to meet this demand. Our actual results may differ materially from these plans and expectations, and the impact and the duration of the COVID-19 pandemic is unknown. Included in these forward-looking statements are statements regarding the impact of the COVID-19 pandemic on Bio-Rad's results and operations and steps Bio-Rad is taking in response to the pandemic. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. With me on the phone today are Norman Schwartz, our Chief Executive Officer Ilan Daskal, Executive Vice President and Chief Financial Officer Andy Last, Executive Vice President and Chief Operating Officer Annette Tumolo, President of the Life Science Group and Dara Wright, President of the Clinical Diagnostics Group.īefore we begin our review, I would like to caution everyone that we will be making forward-looking statements about management's goals, plans and expectations, our future financial performance and other matters. Today, we will review the first quarter results of 2021. Good afternoon, and thank you all for joining us. Welcome to the Q1 2021 Bio-Rad Laboratories, Inc. Ladies and gentlemen, thank you for standing by. Norman Schwartz - Chairman, CEO & PresidentĪnnette Tumolo - EVP & President, Life Science Groupĭara Wright - EVP & President, Clinical Diagnostics Group ( NYSE: BIO) Q1 2021 Earnings Conference Call Ap6:00 PM ET ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |